Safety and immunogenicity of immunotherapy with Bet v 1–derived contiguous overlapping peptides - 27/06/14
Doi : 10.1016/j.jaci.2014.04.001
François Spertini, MD a 
, Yannick Perrin, MD a, Régine Audran, PhD a, Céline Pellaton, PhD a, Caroline Boudousquié, PhD a, Nathalie Barbier, BSc a, Anne-Christine Thierry, BSc a, Vincent Charlon, PhD b, Christophe Reymond, PhD a, b
, Yannick Perrin, MD a, Régine Audran, PhD a, Céline Pellaton, PhD a, Caroline Boudousquié, PhD a, Nathalie Barbier, BSc a, Anne-Christine Thierry, BSc a, Vincent Charlon, PhD b, Christophe Reymond, PhD a, b a Division of Immunology and Allergy, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
b Anergis SA, Epalinges, Switzerland
| Supported by CTI grant 8566.1 LSPP-LS from the Swiss Federal Department of Economic Affairs, Education, and Research (EAER) and in part by Anergis SA (Route de la Corniche 9B, 1066 Epalinges, Switzerland), the developer of AllerT. |
|
| Disclosure of potential conflict of interest: F. Spertini, V. Charlon, and C. Reymond have received consultancy fees from and/or have stock/stock options in Anergis SA. The rest of the authors declare that they have no relevant conflicts of interest. |
© 2014
American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 134 - N° 1
P. 239 - juillet 2014 Retour au numéro
Article précédent
- Gain-of-function signal transducer and activator of transcription 1 (STAT1) mutation–related primary immunodeficiency is associated with disseminated mucormycosis
- Nilay Kumar, Mary E. Hanks, Prabha Chandrasekaran, Brian C. Davis, Amy P. Hsu, Nicholas J. Van Wagoner, Jessica S. Merlin, Christine Spalding, Ricardo M. La Hoz, Steven M. Holland, Christa S. Zerbe, Elizabeth P. Sampaio
- VE-cadherin, a potential marker for endothelial cell activation during hereditary angioedema attacks
- Laurence Bouillet, Isabelle Vilgrain
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?